| 0.6642 -0.016 (-2.32%) | 06-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.87 | 1-year : | 1.02 |
| Resists | First : | 0.75 | Second : | 0.87 |
| Pivot price | 0.66  |
|||
| Supports | First : | 0.63 | Second : | 0.56 |
| MAs | MA(5) : | 0.67  |
MA(20) : | 0.64 |
| MA(100) : | 0.69 |
MA(250) : | 0.85 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 58.1 |
D(3) : | 61.7 |
| RSI | RSI(14): 51.7 |
|||
| 52-week | High : | 3.44 | Low : | 0.5 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ TRIB ] has closed above bottom band by 49.4%. Bollinger Bands are 9.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.7 - 0.7 | 0.7 - 0.71 |
| Low: | 0.64 - 0.65 | 0.65 - 0.65 |
| Close: | 0.66 - 0.66 | 0.66 - 0.67 |
Trinity Biotech plc, an Irish enterprise founded in 1992 and headquartered in Bray, is engaged in the acquisition, development, manufacturing, and global distribution of medical diagnostic solutions. The company's reach extends to the Americas, Africa, Asia, and Europe, catering to both clinical laboratory and point-of-care diagnostic markets. Its extensive range of clinical laboratory offerings encompasses diagnostic tests and specialized instrumentation for identifying numerous infectious diseases. These include Lyme disease, sexually transmitted infections like syphilis and herpes, SARS-CoV-2, and a variety of viral pathogens such as Epstein Barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, and varicella. Additionally, Trinity Biotech provides in-vitro diagnostic products centered on haemoglobin A1c for the crucial monitoring, diagnosis, and risk assessment of diabetes. The company's product development incorporates diverse assay formats, including immunofluorescence, enzyme-linked immunosorbent (ELISA), Western blot, and line immunoassays. It also supplies a suite of reagent products, including ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase, vital for diagnosing liver and kidney disorders, as well as haemolytic anaemia. Beyond diagnostics, Trinity Biotech serves the life sciences industry and research facilities by supplying raw materials. The company's customer base comprises public health authorities, non-governmental organizations, and both clinical and reference laboratories. Its products are distributed through a dedicated direct sales force, complemented by a broad network of independent distributors and strategic partnerships.
Mon, 08 Jun 2026
TRIB Technical Analysis & Stock Price Forecast - Intellectia AI
Fri, 05 Jun 2026
[6-K] TRINITY BIOTECH PLC Current Report (Foreign Issuer) | TRIB SEC Filing - Form 6-K - Stock Titan
Fri, 05 Jun 2026
TRIB Stock Chart | TRINITY BIOTECH PLC-SPON ADR (NASDAQ:TRIB) - ChartMill
Thu, 04 Jun 2026
Trinity Biotech (TRIB) registers 33.75M ADSs (675M shares) for resale - Stock Titan
Mon, 25 May 2026
[EFFECT] TRINITY BIOTECH PLC SEC Filing - Stock Titan
Tue, 10 Mar 2026
Trinity Biotech Provides Business and Trading Update - Yahoo Finance UK
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 20 (M) |
| Shares Float | 324 (M) |
| Held by Insiders | 16.5 (%) |
| Held by Institutions | 5.3 (%) |
| Shares Short | 243 (K) |
| Shares Short P.Month | 403 (K) |
| EPS | -2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.94 |
| Profit Margin | -85.4 % |
| Operating Margin | -10 % |
| Return on Assets (ttm) | -5.8 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.83 |
| Sales Per Share | 2.16 |
| EBITDA (p.s.) | -0.41 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -0.34 |
| PEG Ratio | 0.3 |
| Price to Book value | -0.23 |
| Price to Sales | 0.3 |
| Price to Cash Flow | -2.27 |
| Dividend | 1.1 |
| Forward Dividend | 0 |
| Dividend Yield | 165.6% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|